No Prescription |
 |
 | ||
|
SUMINAT Imitrex |
|
| ||
No Prescription » Prescription Drugs 15 » SUMINAT Imitrex Sumatriptan is a headache medicine. It is believed to work by narrowing the blood vessels around the brain. Sumatriptan also reduces substances in the body that can trigger headache pain nausea sensitivity to light and sound and other migraine symptoms.Sumatriptan tablets and nasal spray are used to treat migraine headaches.Sumatriptan will only treat a headache that has already begun. It will not prevent headaches or reduce the number of attacks. Buy SUMINAT Imitrex and other Prescription Drugs 15 products online at Medstore. 3498
About SUMINAT Imitrex: Product Type: Prescription Drugs 15 SUMINAT ( Imitrex Imigran Generic Sumatriptan ) SUMINAT (Imitrex Imigran Generic Sumatriptan) Imitrex Imigran Generic Sumatriptan 100mg Pack ( 6 x 1 ) Imitrex Imigran Generic Sumatriptan SUMINAT
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
